Position in PHVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$22,884,871
+$4,793,713 QoQ
Shares Held
661,795
+3.3% QoQ
Ownership
0.943%
of shares outstanding
% of Portfolio
1.26%
of 13F equity value
Holder Rank
#25
of 124 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PHVS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Kynam Capital Management, LP holds $1,765,169,848 across 29 Biotechnology names. PHVS ranks #18 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CLDX |
Celldex Therapeutics, Inc.
|
5,322,908 | $198,065,406 | |
| 2 | SNDX |
Syndax Pharmaceuticals Inc
|
8,050,959 | $175,993,963 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
2,922,335 | $169,875,333 | |
| 4 | COGT |
Cogent Biosciences, Inc.
|
3,667,097 | $141,916,653 | |
| 5 | VERA |
Vera Therapeutics, Inc.
|
2,890,059 | $124,012,431 | |
| 6 | VRDN |
Viridian Therapeutics, Inc.\DE
|
6,453,877 | $118,557,720 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
2,000,000 | $113,620,000 | |
| 8 | BEAM |
Beam Therapeutics Inc.
|
2,840,792 | $97,495,981 |
All Filings in PHVS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $22,884,871 | 661,795 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $18,091,158 | 640,395 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $17,770,961 | 640,395 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $16,841,250 | 675,000 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||